SEC Filings
ARK Reports 8.36% Of Recursion's Class A Shares And Certifies A Passive Purpose
The investment manager's September 30 position covered 44,745,024 shares in the AI drug developer.
Recursion Pharmaceuticals (RXRX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The investment manager's September 30 position covered 44,745,024 shares in the AI drug developer.
SEC Filings
The position covered 30,001,137 common shares as of September 30, 2026, rather than a stake bought to influence control.
Earnings
CEO Najat Khan put the market for REC-4881 at roughly $15 billion and said a pivotal study is targeted for the second half of 2027.
SEC Filings
The amended deal adds a year and drops the termination option, while Tempus separately pays $12.0 million to license Recursion's RNA model.
SEC Filings
The AI drug developer's revenue hit $18.6 million on a Sanofi milestone, and it named pharma veteran Fred Hassan chair.
SEC Filings
The offering is priced below the $3.74 last sale on October 14, and the new shares equal 10.3% of the count outstanding afterward.
SEC Filings
The offering of 61,540,000 shares came with a $561 million preliminary cash estimate and a Sanofi milestone worth $10 million.